scispace - formally typeset
J

Joel LeMaoult

Researcher at University of Paris

Publications -  90
Citations -  6527

Joel LeMaoult is an academic researcher from University of Paris. The author has contributed to research in topics: HLA-G & Immune system. The author has an hindex of 42, co-authored 86 publications receiving 5901 citations. Previous affiliations of Joel LeMaoult include Cornell University & Memorial Sloan Kettering Cancer Center.

Papers
More filters
Journal ArticleDOI

HLA-G: from biology to clinical benefits

TL;DR: The clinical implications of HLA-G as a tolerogenic molecule promoting uterine implantation of the embryo or acceptance of solid allografts while allowing the evasion of tumors or viruses from the immune response are reported.
Journal ArticleDOI

Beyond the increasing complexity of the immunomodulatory HLA-G molecule.

TL;DR: The case for considering HLA-G as clinically relevant in pathologic conditions, such as transplantation, autoimmunity, and cancer and hematologic malignancies, is strengthened by what is considered here what are recent key basic findings on the immunomodulatory function of Hla-G.
Journal ArticleDOI

HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells

TL;DR: It is shown here that HLA-G1+ APCs are immunoinhibitory cells that inhibit the proliferation of CD4+ T cells, shed HLA -G1 molecules that might provide extra, non-antigen-specific, inhibitory or proapoptotic signals, and induce CD4- T cell anergy, or at least long-term unresponsiveness.
Journal ArticleDOI

Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense.

TL;DR: Mhc polymorphism-driven diversification of the cytotoxic T lymphocyte (CTL) repertoire is linked to the generation of high-avidity, protective antiviral T cells and to superior antiviral defense.
Book ChapterDOI

HLA-G: An Immune Checkpoint Molecule.

TL;DR: This work focuses on transplantation and oncology because these pathological contexts have been studied the most and also because they best represent the two opposite sides of HLA-G: beneficial to be promoted, or deleterious to be blocked.